The global Artificial Intelligence In Drug Discovery Market was valued at USD 2.3 billion in 2025 and is projected to grow from USD 2.9 billion in 2026 to USD 13.8 billion by 2033, registering a remarkable CAGR of 24.8% from 2026 to 2033. North America dominated the market with a 52.8% revenue share in 2025, supported by strong pharmaceutical research capabilities, advanced AI infrastructure, increasing biotechnology investments, and the presence of leading AI-driven drug discovery companies.

The market is experiencing rapid expansion as pharmaceutical companies increasingly leverage artificial intelligence to reduce drug development timelines, improve clinical success rates, and lower research costs. Traditional drug discovery is often associated with lengthy development cycles, high failure rates, and significant financial investments. AI-powered platforms are transforming this process by enabling researchers to rapidly analyze vast biological, chemical, genomic, and clinical datasets to identify promising therapeutic candidates with greater speed and precision.

Growing demand for cost-effective drug development, increasing clinical trials focused on drug repurposing, rising prevalence of chronic diseases, and expanding adoption of precision medicine are key factors driving market growth. Improvements in cloud computing, high-performance computing infrastructure, and machine learning algorithms are further accelerating AI adoption across pharmaceutical research and development.

Artificial Intelligence Revolutionizing Drug Discovery

Artificial intelligence is reshaping every stage of the drug discovery pipeline by improving decision-making, reducing experimental workloads, and accelerating candidate identification.

Key AI technologies transforming drug discovery include:

• Machine learning algorithms
• Generative AI models
• Natural language processing (NLP)
• Deep learning platforms
• Predictive analytics
• Multi-omics data integration
• Molecular modeling and simulation
• Cloud-based computational drug discovery

Download a free sample copy of the Artificial Intelligence In Drug Discovery Market report to understand detailed coverage and inclusions in the final report

According to an article published in the Frontiers in Pharmacology Journal in October 2025, conventional drug discovery typically requires more than a decade and often costs over USD 2 billion per approved drug. AI-enabled drug repurposing offers a more efficient alternative by identifying new therapeutic uses for existing approved or investigational drugs, reducing development timelines to approximately 3–12 years with an average investment of around USD 300 million.

AI significantly improves this process by analyzing extensive chemical libraries, biomedical literature, genomic datasets, real-world evidence, and clinical trial information to identify high-probability drug candidates while minimizing unnecessary experimental screening. This enables pharmaceutical companies to improve research productivity, reduce financial risk, and accelerate the delivery of innovative therapies.

Emerging Industry Trend: Generative AI and Foundation Models for Drug Design

A major trend transforming the artificial intelligence in drug discovery market is the rapid adoption of generative AI and foundation models for molecular design. Advanced AI models are increasingly capable of generating novel molecular structures, predicting protein-ligand interactions, optimizing drug properties, and identifying potential toxicity risks during early-stage research. These capabilities are accelerating lead optimization while supporting precision medicine initiatives by enabling the development of highly targeted therapies tailored to specific patient populations.

Precision Medicine Driving AI Adoption

The growing emphasis on precision medicine is significantly increasing demand for AI-powered drug discovery platforms.

Artificial intelligence enables researchers to:

• Identify disease biomarkers
• Analyze genomic and transcriptomic data
• Predict patient responses to therapies
• Support companion diagnostics
• Accelerate targeted drug development
• Improve clinical trial design

By integrating multi-omics datasets with advanced machine learning algorithms, AI allows pharmaceutical researchers to develop personalized treatment strategies that improve therapeutic outcomes while reducing adverse effects.

Looking for more specific insights? Customize this report to suite your business needs

Key Market Trends & Insights

Drug Optimization and Repurposing Leads the Market

• By application, the drug optimization and repurposing segment accounted for the largest revenue share of 52.4% in 2025.
• Growing demand for cost-effective drug development strategies continues to drive adoption of AI-enabled repurposing platforms.
• Generative AI models identify novel drug-target interactions, while natural language processing (NLP) extracts valuable insights from biomedical literature, patents, and clinical trial databases to accelerate therapeutic discovery.

Oncology Represents the Largest Therapeutic Area

• By therapeutic area, the oncology segment held the largest revenue share of 24.3% in 2025.
• AI is transforming oncology research by identifying cancer biomarkers, analyzing genomic mutations, predicting pathway dependencies, and supporting precision oncology drug development.
• For example, in June 2025, Revolution Medicines and Iambic Therapeutics announced a multi-year AI collaboration utilizing NeuralPLexer technology for protein-ligand prediction to accelerate development of novel oncology therapeutics.

Academic and Research Institutes Witness Fastest Growth

• By end use, the academic and research institutes segment is expected to register the fastest CAGR from 2026 to 2033.
• Research institutions continue to develop innovative AI algorithms, predictive modeling approaches, and multi-omics integration techniques that improve identification of promising therapeutic candidates while advancing computational drug discovery research.

Regional Highlights

• Largest Regional Market: North America (52.8% revenue share, 2025)
• Fastest Growing Regional Market: Asia Pacific (Highest CAGR, 2026–2033)
• Leading Country: United States

North America maintains its leadership due to strong pharmaceutical R&D investments, advanced biotechnology ecosystems, supportive regulatory initiatives, and early adoption of artificial intelligence technologies. Meanwhile, Asia Pacific is expected to experience the fastest growth as governments and private organizations continue investing in biotechnology innovation, precision medicine, AI infrastructure, and pharmaceutical research capabilities across China, India, Japan, South Korea, and Singapore.

Market Size & Forecast

• Market Size (2025): USD 2.3 Billion
• Estimated Market Size (2026): USD 2.9 Billion
• Projected Market Size (2033): USD 13.8 Billion
• CAGR (2026–2033): 24.8%

The market continues to expand as pharmaceutical companies increasingly adopt artificial intelligence to accelerate drug discovery, optimize candidate selection, reduce development costs, and improve clinical success rates. The integration of machine learning, deep learning, generative AI, cloud computing, and real-world evidence analytics is enabling researchers to identify novel therapeutic opportunities more efficiently while supporting personalized medicine and precision drug development.

Competitive Landscape

Leading companies operating in the artificial intelligence in drug discovery market are strengthening their competitive positions through strategic partnerships, AI platform innovation, cloud-enabled research infrastructure, and investments in computational biology and precision medicine.

Key strategic priorities include:

• Generative AI-driven molecular design
• Drug repurposing platforms
• AI-powered biomarker discovery
• Multi-omics data integration
• Predictive toxicology and clinical analytics
• Strategic pharmaceutical collaborations

Industry participants are increasingly collaborating with pharmaceutical companies, biotechnology firms, research institutions, and healthcare organizations to accelerate drug development and improve research productivity. New product launches, technology partnerships, and AI platform enhancements remain central strategies supporting market expansion.

Explore Grand View Horizon to see global and regional level statistics related to the Artificial Intelligence In Drug Discovery Market

Key Artificial Intelligence in Drug Discovery Companies

The following companies are among the leading participants operating in the global artificial intelligence in drug discovery market:

• Healx
• BostonGene Corporation
• BenevolentAI
• Innophore
• Delta4.ai
• BioXcel Therapeutics Inc.
• BullFrog AI Holdings, Inc.
• Graphwise
• Owkin, Inc.
• Insilico Medicine
• IBM
• Exscientia
• Google (DeepMind)
• BioSymetrics, Inc.
• BPGbio Inc. (Berg Health)
• Atomwise Inc.
• Recursion
• Aitia
• insitro

Conclusion

The artificial intelligence in drug discovery market is poised for substantial growth as pharmaceutical and biotechnology organizations increasingly adopt AI-driven platforms to transform research and development processes. Rising demand for faster, more cost-effective drug development, expanding applications in precision medicine, and growing interest in drug repurposing are accelerating market adoption worldwide. Advances in generative AI, machine learning, cloud computing, and multi-omics analytics are enabling researchers to identify promising therapeutic candidates with greater speed and accuracy while reducing development risks and costs. Companies that combine advanced AI technologies with strong pharmaceutical expertise, strategic collaborations, and scalable computational platforms will be well-positioned to lead the next generation of drug discovery innovation.

Looking for a report customized to your requirements? Explore our Custom Research Offering

Grand View Research offers

• Focused market intelligence reports on specific geographies or high-growth segments
• Extended forecast timelines for long-term planning
• Competitor Benchmarking and Supply Chain Analysis
• Inclusion of regulatory and policy assessments
• Inclusion of custom data models, KPIs, or applications unique to your business
• Specific high-impact Data Decks and Tables to support effective decision making

And much more…